Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Patents (Class 514/456)
  • Patent number: 10646467
    Abstract: Method of treating endometriosis and related indications, comprising the administration of Pro-EGCG, a synthetic and derivative product of epigallocatechin-3-gallate [(?)-EGCG]. Use of PRO-EGCG in the manufacture of a medicament for treating endometriosis and related indications. Pro-EGCG for use in the treatment of endometriosis and related indications.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: May 12, 2020
    Inventors: Tak-Hang Chan, Chi-Chiu Wang
  • Patent number: 10646465
    Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 12, 2020
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Abraham, Orly Eizenberg
  • Patent number: 10632098
    Abstract: The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chiysoeriol, Cosmosiin and Flavocannabiside or their synthases, for the prevention and treatment of certain ocular diseases and related disorders.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: April 28, 2020
    Inventors: Henry I C Lowe, Ngeh J. Toyang
  • Patent number: 10626109
    Abstract: The present invention relates to fungicidal N-hetarylcarbonyl-2-(benzocycloalken-1-yl)piperidines or pyrrolidines of formula (I), and their thiocarbonyl derivatives, wherein A represents a carbo-linked, unsaturated or partially saturated, 5-membered heterocyclyl group that can be substituted by up to four groups R that can be the same or different; T represents 0 or S; n represents 1 or 2; m represents 1, 2 or 3; p represents 1, 2, 3 or 4, L1 and L2 independently represent CZ4Z5, NZ6, 0, S, S(O) or S(0)2; and R and Z1-Z6 are as defined in the claims; their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: April 21, 2020
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Philippe Desbordes, Philippe Rinolfi, Tomoki Tsuchiya
  • Patent number: 10603349
    Abstract: The present invention relates to a method for preparing a granulate composition of rhizomes from Alpinia galanga or Alpinia conchigera having a high and stable content of 1?S-1?-acetoxychavicol acetate and low microbiological count, which is suitable for preparing orally ingestible dosage forms such as tablets or capsules.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: March 31, 2020
    Assignee: NERTHUS APS
    Inventors: Henrik Byrial Jakobsen, Ina Giversen
  • Patent number: 10596185
    Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 levels, treating inflammation, and treating symptoms of metabolic syndrome.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: March 24, 2020
    Assignees: INGREDIENTS BY NATURE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: Robert M. Brewster, John A. Manthey
  • Patent number: 10548938
    Abstract: The object is to provide a method of manufacturing a fraction containing nobiletin and tangeretin at high concentrations, which is excellent in terms of safety, economic efficiency, and the potential for industrialization. The method includes (1-1) a step of treating citrus fruit with hot water to obtain a hot water-treated product; (1-2) a step of drying the hot water-treated product to obtain a dried product; (1-3) a step of treating the dried product with a solvent capable of dissolving nobiletin and tangeretin to obtain a nobiletin and tangeretin solution; (3) a step of concentrating and/or drying the nobiletin and tangeretin solution to obtain a nobiletin and tangeretin concentrate; and (4) a step of treating the nobiletin and tangeretin concentrate with a dilute alkali to obtain a composition containing nobiletin and tangeretin as an insoluble component, and by a composition containing nobiletin and tangeretin at high concentrations manufactured by the method.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: February 4, 2020
    Assignees: UNIVERSITY OF THE RYUNKYUS, OKINAWA RESEARCH CENTER CO., LTD.
    Inventors: Toshiaki Teruya, Yuto Teruya, Saki Sugiyama, Je-Tae Woo
  • Patent number: 10543277
    Abstract: A medicinal composition useful for the treatment of head and neck cancer premalignant lesions. The composition includes a curcuminoid mixture and an essential oil of turmeric. The curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin. The essential oil of turmeric includes about 45% ar-turmerone. The weight ratio of curcuminoid mixture to essential oil of turmeric ranges from about 1:3 to about 99:1. Methods of preparation of the composition is provide. Methods of treatment of head and neck cancer premalignant lesions by oral administration is provided.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: January 28, 2020
    Assignee: ARJUNA NATURAL PRIVATE LIMITED
    Inventors: Benny Antony, Moni Abraham Kuriakose
  • Patent number: 10544157
    Abstract: The present invention provides a process for the preparation of darunavir or solvates or a pharmaceutically acceptable salt thereof substantially free of bisfuranyl impurities, particularly darunavir propionate solvate. The present invention also provides a process for preparation amorphous darunavir using the darunavir propionate solvate.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: January 28, 2020
    Assignee: LAURUS LABS LIMITED
    Inventors: Kameswar R. Chivukula, Venkata R. Murthy, Venkata S. Indukuri, Seeta R. Gorantla
  • Patent number: 10537547
    Abstract: Disclosed are methods of favouring epithelial wound healing in a subject. Wounds suitable for this method include wounds located on the skin or in a cornea The methods comprise contacting a wound with an activator of an AKT pathway and/or an inhibitor of the MAPK pathway such as CREB inhibitors. Preferred compounds include SC-79, C646, curcumin, platelet-derived growth factor, 4?chloro-3-hydroxy-2-naphthanilide and fumonisin B. A model for wound healing is also disclosed. The model can be used to identify test compounds that are AKT activators or inhibitors of MAPK pathway, which are suitable to favoring epithelial wound healing.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 21, 2020
    Inventors: Sylvain Guerin, Lucie Germain, Karine Zaniolo, Camille Couture, Pascale Desjardins
  • Patent number: 10500145
    Abstract: A temporary tattooing ink is produced from concentrated genipin. In one embodiment, the concentrated genipin forms part of a solution. In another embodiment, the genipin is provided in a gel form which also includes a solvent and a thickening agent. Finally, an applicator is described into which genipin may be embedded for applying to a user's skin.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 10, 2019
    Assignee: inkbox ink inc.
    Inventors: Tyler James Handley, Braden Handley, Christopher Blain Caputo, Adam Manuel Zrehen
  • Patent number: 10392400
    Abstract: Provided herein are palladium-mediated coupling reactions useful in the preparation of ketone-containing organic molecules. The provided methods can be used for the preparation of natural products and pharmaceutical agents, including Eribulin, halichondrins, and analogs thereof. The present invention also provides novel halichondrin analogs which can be prepared via the palladium-mediated coupling reactions. The novel halichondrin analogs can be used in the prevention and/or treatment of diseases or conditions (e.g., proliferative diseases such as cancer).
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 27, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Jung Hwa Lee, Yoshito Kishi, Ayumi Osawa, Zhanjie Li
  • Patent number: 10392361
    Abstract: The present invention relates to a novel process for the synthesis of the intermediate compounds constituted by chromanyl haloketones of formula III and 6-fluoro-2-(oxiran-2-yl)chromans of formula I. The intermediates thus obtained can be used for the synthesis of Nebivolol.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: August 27, 2019
    Assignee: Menarini International Operations Luxembourg S.A.
    Inventors: Sandra Bartoli, Serena Mannucci, Alessio Griselli, Alessio Stefanini
  • Patent number: 10391113
    Abstract: Disclosed are a compound pharmaceutical composition containing Cichorium glandulosum Boiss et Hout as a lipid-lowering active ingredient and the use of the composition for preparing a drug for treating or preventing lipid metabolism disorders, wherein the composition comprises a pharmaceutically active ingredient and a pharmaceutically acceptable carrier, wherein the pharmaceutically active ingredient consists of quercetin-3-O-?-D-glucuronoside, isoquercitrin and quercetin at a molar ratio of 1.1-2.4:1.3-3.3:1.2-3.1.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: August 27, 2019
    Assignee: NANJING RUIYING RUNZE BIOPHARMAEUTICAL TECHNOLOGY CO., INC.
    Inventors: Jing Shang, Lin Ding, Guohong Qin, Tao Wang, Jun Liu, Yu Li, Ting He
  • Patent number: 10370364
    Abstract: A compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof: wherein R1 is a substituted or unsubstituted C1-5 linear or branched alkyl, a C5-6 cycloalkyl, a C5-6 cycloalkyl containing at least one heteroatom selected from among O and N, a substituted or unsubstituted C6-12 aryl, or a C5-6 heteroaryl containing at least one heteroatom selected from among O and N; R2 is hydrogen, ethyl, acetyl, acetoxy, carboxy, benzoyloxy or 3,4,5-trihydroxybenzoyloxy; and R3 to R5 are each independently hydrogen, hydroxyl, methyl, methoxy, acetoxy, carboxy or benzoyloxy.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: August 6, 2019
    Assignee: OSTEONEUROGEN INC.
    Inventors: Byung Soo Youn, Jun Hwan Kim, Han Soo Kim, Ho Sup Yoon, Ik Hwan Kim
  • Patent number: 10369132
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: August 6, 2019
    Assignee: MEI PHARMA, INC.
    Inventor: Ofir Moreno
  • Patent number: 10370350
    Abstract: The present disclosure relates to salts of the compound (I), polymorphic forms thereof, methods for preparation and use thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: August 6, 2019
    Assignee: Research Development Foundation
    Inventors: Michael O'Neill, Barbara Kidon, Thomas Adkins, Hongqiao Wu, Emmanuel T. Akporiaye
  • Patent number: 10342777
    Abstract: A caffeoylquinic acid-rich extract obtained from Erigeron multiradiatus and a method for producing the same. A caffeoylquinic acid-rich extract includes at least 15% by weight of a mixture of certain caffeoylquinic acids. The extract with the mixture of caffeoylquinic acids is highly efficacious in treating and preventing myocardial ischemia or myocardial ischemia reperfusion injuries. A method for treating or preventing a disease caused by myocardial ischemia or myocardial ischemia reperfusion includes administering a therapeutically effective amount of the caffeoylquinic acid-rich extract to a subject. Pharmaceutical compositions including the caffeoylquinic acid-rich extract are also disclosed.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: July 9, 2019
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Pei Luo, Zhifeng Zhang, Hao Zhang
  • Patent number: 10322130
    Abstract: The present invention provides PI3K protein kinase modulators of formula wherein R, Cy1, R1, R2, L1 and Cy2 are as defined herein. The present invention also relates to methods of preparing compounds of formula (I) to pharmaceutical compositions containing them and to methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: June 18, 2019
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant K. Bhavar
  • Patent number: 10316053
    Abstract: The present disclosure provides a compound of the following formula, racemates, enantiomers, prodrugs and salts thereof: Also provided is the use of these compounds for the treatment of ischemia and reperfusion injuries. Further applications include the treatment of diseases caused by cell apoptosis and/or cell necrosis.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 11, 2019
    Assignee: ARMARON BIO PTY LTD
    Inventor: Grant McLachlan
  • Patent number: 10314810
    Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: June 11, 2019
    Assignees: Trustees of Boston University, Northeastern University, Boston Medical Center Corporation
    Inventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
  • Patent number: 10294239
    Abstract: The present invention relates to processes for the preparation of an ertugliflozin-L-pyroglutamic acid (1:1) and co-crystal ertugliflozin-L-proline (1:1) co-crystal. The present invention further relates to an ertugliflozin-L-proline (1:2) co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: May 21, 2019
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Ramkinkar Santra, Bala Krishna Reddy Bhogala, Chandra Has Khanduri
  • Patent number: 10238625
    Abstract: Methods for the treatment of systemic mast cell related disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 26, 2019
    Assignee: RESPIVANT SCIENCES GMBH
    Inventors: William Gerhart, Pravin Soni, Ahmet Tutuncu
  • Patent number: 10206901
    Abstract: A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, terpenes such as linalool.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: February 19, 2019
    Assignee: JC Pharma, Inc.
    Inventors: Jason Allen Cranford, Donald Channing Cooper
  • Patent number: 10188747
    Abstract: The technology described herein is directed to agonists of, e.g. Esr2, Dlx5, and/or Egr3, for the inhibition of cancer cells (e.g. squamous carcinoma cancer cells) and the treatment of cancer.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: January 29, 2019
    Assignee: The General Hospital Corporation
    Inventors: Gian Paolo Dotto, Yang Sui Brooks
  • Patent number: 10105346
    Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: October 23, 2018
    Assignee: MEI PHARMA, INC.
    Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
  • Patent number: 10105344
    Abstract: The present invention is directed to methods for reducing blood lactate concentration during exercise, physical activity or athletic performance.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: October 23, 2018
    Assignee: Stokely-Van Camp, Inc.
    Inventors: Jeffrey J. Zachwieja, Mark Arthur Pirner, JohnEric William Smith
  • Patent number: 10098915
    Abstract: An equol-producing lactic acid bacteria-containing composition comprises, as an essential component thereof, a lactic acid bacterial strain belonging to the genus Lactococcus having an ability to utilize at least one daidzein compound selected from the group consisting of daidzein glycosides, daidzein, and dihydrodaidzein to produce equol. Such a composition is effective for the prevention and alleviation of malaise inclusive of climacteric disturbance in middle-aged and elderly women for which no effective prophylactic method or alleviating means has heretofore been available.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: October 16, 2018
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Shigeto Uchiyama, Tomomi Ueno, Toshimi Suzuki
  • Patent number: 10072055
    Abstract: Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: September 11, 2018
    Assignee: Resother Pharma APS
    Inventors: Angelo P. Consalvo, Nozer M. Mehta, Mauro Perretti, Jesmond Dalli
  • Patent number: 10045961
    Abstract: Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: August 14, 2018
    Assignee: Drexel University
    Inventors: Jinhong Chang, Fang Guo, Timothy M. Block, Ju-Tao Guo
  • Patent number: 10039739
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: August 7, 2018
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Patent number: 10039725
    Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 7, 2018
    Assignees: ChromaDex Inc., The Regents of the Unviersity of California
    Inventors: Jeremy Bartos, Ryan Dellinger
  • Patent number: 10028970
    Abstract: The invention concerns a cashew apple extract and a composition comprising a cashew apple extract and optionally a carrier, in particular for use for allowing reduction of body weight gain or limitation of increasing body weight, reduction or limitation of fat storage, of fatty liver, of liver triglycerides level, of hypertriglyceridemia, of glycemia level, of insulinemia, of insulin resistance, and/or of one or several factors of metabolic syndrome.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: July 24, 2018
    Assignee: NATUREX
    Inventors: Nicolas Chapal, Max Reynes, Vickram Beejmohun, Manuel Dornier
  • Patent number: 9981936
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 29, 2018
    Assignee: MEI Pharma, Inc.
    Inventor: Ofir Moreno
  • Patent number: 9975868
    Abstract: In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: May 22, 2018
    Assignee: Emory University
    Inventor: Keqiang Ye
  • Patent number: 9962364
    Abstract: The purpose of the present invention is to provide a specific wound healing accelerator effective for accelerating healing of wounds, particularly of wounds in the oral cavity, or a composition which includes the wound healing accelerator. This wound healing accelerator including a specific polyphenol is easy to handle and is capable of accelerating would healing even by contact for a short time.
    Type: Grant
    Filed: December 25, 2013
    Date of Patent: May 8, 2018
    Assignee: A-Z LTD.
    Inventors: Yoshimi Niwano, Taro Kanno, Keisuke Nakamura, Minoru Kanno
  • Patent number: 9956199
    Abstract: The present invention relates to certain chromane-like cyclic prenylflavonoids, in particular the compounds of formulae (I), (II) and (III) as described and defined herein, for use in the treatment or prevention of a neurological disorder, as well as their use in promoting neuronal differentiation, neurite outgrowth and neuroprotection.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 1, 2018
    Inventors: Ludwig Aigner, S├ębastien Couillard-Despres
  • Patent number: 9901565
    Abstract: The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: February 27, 2018
    Assignee: Protectea, Ltd.
    Inventors: Kunihiro Kaihatsu, Shuichi Mori, Tomo Daidoji, Nobuo Kato, Shinya Miyake
  • Patent number: 9877946
    Abstract: A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of UCP-1 and PRDM4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: January 30, 2018
    Assignees: Research & Business Foundation Sungkyunkwan University, GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR
    Inventors: Kye Won Park, Nojoon Song, Suk Chan Lee, Jin-Mo Ku
  • Patent number: 9861610
    Abstract: The present invention relates to a process for selective extraction of bioactive and bioavailable cinnamon polyphenols and procyanidin oligomers of the type A and type B, of more than 90% purity as gallic acid equivalent which comprises the steps of removing the organic solvent from the extract to produce the free flowing oleoresin and drying of the residue under optimized conditions to produce a polyphenol and procyanidin Type A & B polymer rich solid which on subsequent extraction with water or with mixture of water and acetone or water and lower alcohol and further evaporation to a solid content of not more than 6% and subsequent chromatographic separation to obtain fractions containing procyanidin type A and B polymers free of coumarins and cinnamaldehyde. The present invention also relates to stable composition comprising cinnamon polyphenol rich powder for delivering maximum bioactivity upon oral administration.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: January 9, 2018
    Assignee: AKAY FLAVOURS & AROMATICS PVT LTD.
    Inventors: Krishnakumar Illathu Madhavamenon, Abin Isaac, Dineshkumar Unnikrishnan, Aswin Koshy Jacob Vaidyan, Balu Paulose Maliakel
  • Patent number: 9855204
    Abstract: A treatment method including: (a) identifying a subject in need of treatment for androgenic alopecia (AGA), and (b) orally administering a physiologically effective amount of cepharanthine (CEP) to the subject according to a dosage regimen.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: January 2, 2018
    Inventor: Moshe Rogosnitzky
  • Patent number: 9848624
    Abstract: The invention relates to the use of rubusoside and certain mixtures containing rubusoside, preferably the use of certain rubusoside-containing mixtures, in particular Rubus suavissimus extracts, for masking, reducing or suppressing a bitter, sour and/or astringent taste impression. The invention further relates to orally consumable preparations, comprising at least one bitter, sour and/or astringent-tasting substance and rubusoside or certain rubusoside-containing mixtures, preferably certain Rubus suavissimus extracts, a corresponding method of producing said preparations and a method for reducing or suppressing the bitter, sour and/or astringent effect of a bitter, sour and/or astringent-tasting substance. The invention further relates to certain flavoring compositions that are particularly effective for masking, reducing or suppressing a bitter, sour and/or astringent taste impression.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: December 26, 2017
    Assignee: Symrise AG
    Inventors: Jakob Peter Ley, Katharina Reichelt, Thomas Riess, Kathrin Langer, Susanne Paetz
  • Patent number: 9840512
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: December 12, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Linda L. Brockunier, Helen Chen, Harry R. Chobanian, Matthew J. H. Clements, Alejandro Crespo, Duane E. DeMong, Yan Guo, William K. Hagmann, Karen M. Marcantonio, Michael Miller, Barbara Pio, Christopher W. Plummer, Dong Xiao
  • Patent number: 9782364
    Abstract: Methods for reducing MSK1 levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III. Methods for inhibiting MSK1 serine376 phosphorylation in a plurality of cells are also disclosed, which include providing to the cells a curcumin composition that is at least 5% curcumin III. In addition, methods for ameliorating inflammation in a subject are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. Still further, methods for ameliorating symptoms in a subject having glucocorticoid-resistant inflammatory disease are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. In addition, compositions are disclosed that include a curcumin composition consisting of at least 5% curcumin III; glucocorticoids; and a pharmaceutically acceptable solvent, filler, or carrier.
    Type: Grant
    Filed: August 14, 2016
    Date of Patent: October 10, 2017
    Inventor: Franco Cavaleri
  • Patent number: 9775825
    Abstract: The present disclosure is related to management of chemotherapy induced side effects namely cachexia and alopecia by administering a pharmaceutical composition comprising pentameric type A procyanidin flavonoid, trimeric procyanidin flavonoid and tetrameric procyanidin flavonoid, optionally along with pharmaceutical excipients.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: October 3, 2017
    Assignee: Indus Biotech Private Limited
    Inventors: Sunil Bhaskaran, Mohan Vishwaraman
  • Patent number: 9763910
    Abstract: Disclosed is a method of treating a subject having non-small cell lung cancer. The method includes administering to the subject a therapeutically effective amount of a composition and the composition contains 5-demethylnobiletin and docetaxel. Compared with the use of docetaxel alone, the method of combining 5-demethylnobiletin and docetaxel had a 4.4 fold increase in inhibiting the growth of human lung cancer cells, and had a 3.05 fold increase in inhibiting tumor growth in human lung cancer cell-engrafted nude mice.
    Type: Grant
    Filed: December 31, 2016
    Date of Patent: September 19, 2017
    Assignee: Huanggang Normal University
    Inventor: Shiming Li
  • Patent number: 9750716
    Abstract: The invention provides safe and efficacious treatments for Female Sexual Disorders, genitopelvic pain/penetration disorders, vulvovaginal atrophy, vestibulodynia, dyspareunia, sexual interest/arousal disorder, low female libido, and female orgasmic disorder.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 5, 2017
    Inventor: Wendy Anne Epstein
  • Patent number: 9745279
    Abstract: The present invention provides a sirtuin activator with an active component composed of black ginger or a black ginger extract, which is easily obtainable, extremely safe, and eaten from old. The present invention further provides a sirtuin activator with an active component of polyalkoxyflavonoid compound represented by general formula (I) and having a sirtuin activation effect that is 10 folds that of resveratrol or higher: wherein, R1 to R7 are each independently a hydrogen atom, a hydroxyl group, or a C1 to C6 lower alkoxy group.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: August 29, 2017
    Assignees: TOKIWA PHYTOCHEMICAL CO., LTD.
    Inventors: Tsutomu Shimada, Jinwei Yang, Yuka Koike
  • Patent number: 9744164
    Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: August 29, 2017
    Assignee: Salk Institute for Biological Studies
    Inventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
  • Patent number: 9724325
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: August 8, 2017
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk